About Fresenius Kabi
Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, we offer products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems.
Fresenius Kabi employs over 35,000 people worldwide. In 2017 the company reported sales of more than €6 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA health care group.
"caring for life"
Fresenius Kabi’s primary responsibility is to help ensure the best possible therapy for patients. In line with our mission “caring for life”, Fresenius Kabi is committed to ensuring Propofol is only used for its intended and clinically approved medical purpose. We object to its use in any manner not in accordance with them:
- Fresenius Kabi has voluntarily initiated actions to impose distribution controls to ensure safe, appropriate and effective access to Propofol in the United States.
- A precondition: Immediate access by medical professionals in all parts of the country must be maintained.
Clearly the use of Propofol for lethal injections is contrary to our mission and not in line with FDA approved indications for Propofol. Fresenius Kabi is doing its utmost to prevent the use of Propofol in executions.